Switch theme
Sign up to access all valuation multiples
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.
2018
35
LTM Revenue $0.6M
LTM EBITDA -$61.4M
$118M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Compass Therapeutics has a last 12-month revenue of $0.6M and a last 12-month EBITDA of -$61.4M.
In the most recent fiscal year, Compass Therapeutics achieved revenue of $0.8M and an EBITDA of -$54.9M.
Compass Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Compass Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | $0.8M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$48.5M | -$54.9M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -6456% | XXX | XXX | XXX |
| Net Profit | -$39.2M | -$42.5M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -4999% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Compass Therapeutics's stock price is $2.
Compass Therapeutics has current market cap of $238M, and EV of $118M.
See Compass Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $118M | $238M | XXX | XXX | XXX | XXX | $-0.39 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Compass Therapeutics has market cap of $238M and EV of $118M.
Compass Therapeutics's trades at 186.8x LTM EV/Revenue multiple, and -1.9x LTM EBITDA.
Analysts estimate Compass Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Compass Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $118M | XXX | XXX | XXX |
| EV/Revenue | 138.5x | XXX | XXX | XXX |
| EV/EBITDA | -2.1x | XXX | XXX | XXX |
| P/E | -4.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -2.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCompass Therapeutics's NTM/LTM revenue growth is 1269%
Compass Therapeutics's revenue per employee for the last fiscal year averaged $24K, while opex per employee averaged $1.6M for the same period.
Over next 12 months, Compass Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Compass Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Compass Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | Infinity% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -6456% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 13% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -5186% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $24K | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.6M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1780% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 4981% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 6762% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Compass Therapeutics acquired XXX companies to date.
Last acquisition by Compass Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Compass Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Compass Therapeutics founded? | Compass Therapeutics was founded in 2018. |
| Where is Compass Therapeutics headquartered? | Compass Therapeutics is headquartered in United States of America. |
| How many employees does Compass Therapeutics have? | As of today, Compass Therapeutics has 35 employees. |
| Who is the CEO of Compass Therapeutics? | Compass Therapeutics's CEO is Dr. Thomas J. Schuetz, M.D.,PhD. |
| Is Compass Therapeutics publicy listed? | Yes, Compass Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Compass Therapeutics? | Compass Therapeutics trades under CMPX ticker. |
| When did Compass Therapeutics go public? | Compass Therapeutics went public in 2020. |
| Who are competitors of Compass Therapeutics? | Similar companies to Compass Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Compass Therapeutics? | Compass Therapeutics's current market cap is $238M |
| What is the current revenue of Compass Therapeutics? | Compass Therapeutics's last 12-month revenue is $0.6M. |
| What is the current EBITDA of Compass Therapeutics? | Compass Therapeutics's last 12-month EBITDA is -$61.4M. |
| What is the current EV/Revenue multiple of Compass Therapeutics? | Current revenue multiple of Compass Therapeutics is 186.8x. |
| What is the current EV/EBITDA multiple of Compass Therapeutics? | Current EBITDA multiple of Compass Therapeutics is -1.9x. |
| Is Compass Therapeutics profitable? | Yes, Compass Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
